A new study examining the gene phosphate and tensin homolog (PTEN) calls for both early detection of cancer and awareness of the importance of precision therapy.
Is it time for us to use pharmacogenomics to find safe and effective doses of tamoxifen for patients — optimizing clinical outcomes with minimal side effects? Dr. Jennifer Hockings discusses.
Differences between indolent and aggressive forms of prostate cancer have been identified based on patterns of DNA methylation according to researchers Lerner Research Institute of the Cleveland Clinic.
Charis Eng, MD, PhD, Chair and Director of Cleveland Clinic’s Genomic Medicine Institute, shares her views on genetics-related Top 10 Innovations.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A multidisciplinary effort involving Cleveland Clinic’s Head & Neck Institute, oncologists and medical geneticists attempts to identify and manage patients with genetic predispositions to paraganglioma.
As genomic analyses reveal increasingly complex information about patients’ cancers, Cleveland Clinic Taussig Cancer Institute Chairman Brian Bolwell, MD, says a collaborative, multidisciplinary approach to care becomes even more important.